AlphaTON Capital Signs $46 Million AI Infrastructure Deal

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: 13 Jan 26

Source: Globenewswire

AlphaTON Capital Corp's stock surged by 214.29% in pre-market trading as it crossed above the 5-day SMA.

The company has signed a $46 million AI compute infrastructure deal, which includes the addition of 576 NVIDIA B300 chips. This strategic investment is projected to deliver a 27% internal rate of return (IRR) and a 282% return on investment (ROI), significantly enhancing AlphaTON's competitive edge in the privacy computing market. The deployment aims to address a critical gap in AI workloads that require privacy and data protection, with expectations of generating $53.6 million in cash returns over the next five years.

This deal positions AlphaTON favorably in the rapidly growing AI infrastructure sector, which is expected to see a surge in demand. The company's focus on sustainability, utilizing renewable energy for its data center operations, aligns with global trends towards green technology, further solidifying its market position.

ATON

$1.3+Infinity%1D

Analyst Views on ATON

About ATON

AlphaTON Capital Corp., formerly Portage Biotech Inc., is a specialized digital asset treasury company. The Company is focused on building and managing a strategic reserve of The Open Network (TON) tokens and developing the Telegram ecosystem. The Company implements a treasury strategy that combines direct token acquisition, validator operations, and strategic ecosystem investments to generate sustainable returns for shareholders. Through its operations, the Company provides public market investors with institutional-grade exposure to the TON ecosystem and Telegram's billion user platform. It is also advancing therapies that target known checkpoint resistance pathways to achieve durable treatment response and improve quality of life for patients. The Company engages in the drug development process and provides strategic counsel to guide development of immunotherapy assets and asset combinations.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

AlphaTON Capital Signs $46 Million AI Infrastructure Deal

Analyst Views on ATON

About ATON

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

AMD Stock Rises 6.39% Following Analyst Upgrade to $270 Target

GFL Environmental Prices $1 Billion Senior Notes Offering

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch